TNSN00231A1 - Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant - Google Patents

Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant

Info

Publication number
TNSN00231A1
TNSN00231A1 TNTNSN00231A TNSN00231A TNSN00231A1 TN SN00231 A1 TNSN00231 A1 TN SN00231A1 TN TNSN00231 A TNTNSN00231 A TN TNSN00231A TN SN00231 A TNSN00231 A TN SN00231A TN SN00231 A1 TNSN00231 A1 TN SN00231A1
Authority
TN
Tunisia
Prior art keywords
crystalline form
compositions containing
tetrahydroquinoleine
substitue
carboxyamino
Prior art date
Application number
TNTNSN00231A
Other languages
English (en)
French (fr)
Inventor
Anthony Appleton Troy
Robinson Brostrom Lyle
Lawrence Tickner Derek
John Meldrum Allen Douglas
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN00231A1 publication Critical patent/TNSN00231A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Quinoline Compounds (AREA)
TNTNSN00231A 1999-11-30 2000-11-29 Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant TNSN00231A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
TNSN00231A1 true TNSN00231A1 (fr) 2002-05-30

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00231A TNSN00231A1 (fr) 1999-11-30 2000-11-29 Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant

Country Status (28)

Country Link
EP (1) EP1246804A1 (es)
JP (1) JP2003515592A (es)
KR (1) KR20020058057A (es)
CN (1) CN1402711A (es)
AP (1) AP2002002531A0 (es)
AU (1) AU1048801A (es)
BG (1) BG106854A (es)
BR (1) BR0015836A (es)
CA (1) CA2392979A1 (es)
CO (1) CO5271716A1 (es)
EA (1) EA200200510A1 (es)
EC (1) ECSP003792A (es)
EE (1) EE200200277A (es)
GT (1) GT200000199A (es)
HU (1) HUP0203521A2 (es)
IL (1) IL149097A0 (es)
IS (1) IS6338A (es)
MA (1) MA26845A1 (es)
MX (1) MXPA02005354A (es)
NO (1) NO20022558L (es)
OA (1) OA12099A (es)
PA (1) PA8506301A1 (es)
PE (1) PE20010904A1 (es)
PL (1) PL355892A1 (es)
TN (1) TNSN00231A1 (es)
TR (1) TR200201446T2 (es)
UY (1) UY26454A1 (es)
WO (1) WO2001040190A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
OA12619A (en) 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
GT200200170A (es) 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
WO2003063822A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
BR0306208A (pt) 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
JP2006508077A (ja) 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
CA2508840A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
MXPA05010456A (es) * 2003-03-28 2006-03-21 Pfizer Prod Inc Compuestos de quinolina y quinoxalina.
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
MXPA06003927A (es) 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
JP4922924B2 (ja) * 2004-04-13 2012-04-25 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｅｔｐ阻害薬
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
US20070149567A1 (en) * 2004-09-23 2007-06-28 Pfizer Inc Quinoline compounds
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
CA2598133A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP2134169A2 (en) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
CN106559998B (zh) 2014-07-30 2022-01-25 豪夫迈·罗氏有限公司 预测对hdl升高剂或hdl模拟剂疗法的应答性的遗传标记

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
AU5731098A (en) * 1997-02-03 1998-08-25 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
BR0015836A (pt) 2002-08-06
OA12099A (en) 2006-05-04
PE20010904A1 (es) 2001-09-10
TR200201446T2 (tr) 2002-11-21
IS6338A (is) 2002-04-12
BG106854A (bg) 2002-12-29
ECSP003792A (es) 2002-04-23
CN1402711A (zh) 2003-03-12
KR20020058057A (ko) 2002-07-12
IL149097A0 (en) 2002-11-10
GT200000199A (es) 2002-05-23
EP1246804A1 (en) 2002-10-09
NO20022558D0 (no) 2002-05-29
MXPA02005354A (es) 2002-12-11
UY26454A1 (es) 2001-07-31
PA8506301A1 (es) 2002-08-26
CO5271716A1 (es) 2003-04-30
PL355892A1 (en) 2004-05-31
HUP0203521A2 (hu) 2003-02-28
MA26845A1 (fr) 2004-12-20
NO20022558L (no) 2002-05-29
WO2001040190A1 (en) 2001-06-07
JP2003515592A (ja) 2003-05-07
EE200200277A (et) 2003-10-15
AU1048801A (en) 2001-06-12
CA2392979A1 (en) 2001-06-07
AP2002002531A0 (en) 2002-06-30
EA200200510A1 (ru) 2002-10-31

Similar Documents

Publication Publication Date Title
TNSN00231A1 (fr) Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98238A1 (fr) Macrolides nouveaux
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97139A1 (fr) Derives d'acides d'arylsulfonylaminohydroxamiques
TNSN99055A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98216A1 (fr) Derives d'acide hydrauxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97144A1 (fr) Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00028A1 (fr) Derives de quinoleine -2-one a substituant heteroaryle nouveaux procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98019A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98112A1 (fr) Composes dipeptidiques
TNSN98182A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
TNSN00033A1 (fr) Composes nouveaux inhibiteurs de reabsorption de monoamines, procede pour leur preparation, et compositions pharmaceutiques les contenant
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98025A1 (fr) Derives d'acide arylsulfonylhydroxamique, procede pour leur preparation et compositions les contenant.